04 Postdoctoral Fellowship at University of Twente, Netherlands

Word jij enthousiast van het verbeteren en toepassen van AI bij het oplossen van klinische uitdagingen? Ben je communicatief vaardig en vind je het leuk om met mensen met verschillende achtergronden samen te werken? Als postdoc onderzoeker binnen de vakgroep M3i en het Rijnstate ziekenhuis maak je deel uit van het door ZonMW gefinancierde AI for EVAR-project, dat erop gericht is de zorg voor patiënten met een abdominaal aorta-aneurysma te transformeren. Je implementeert en valideert geavanceerde multimodal deep learning-modellen die beeldvorming en klinische data integreren om behandel en follow-up strategieën te personaliseren. Daarnaast voer je een vroege HTA analyse uit van de ontwikkelde modellen.

In Nederland wordt ongeveer 75% van de patiënten met een abdominaal aorta-aneurysma  endovasculair behandeld, waarbij een stent wordt geplaatst (EVAR). Hoewel EVAR goede korte-termijn resultaten oplevert, hebben deze patiënten op de lange termijn een verhoogd risico op complicaties en heringrepen. Dit maakt levenslange follow-up noodzakelijk.

University of Twente’s Technical Medical Centre is widely recognized for its excellence in development of new biomedical solutions to address important biomedical challenges. Here, various Departments work on pressing topics with high societal and biomedical relevance such as osteoarthritis. The Developmental BioEngineering department (https://www.utwente.nl/en/tnw/dbe/) is currently recruiting 2 postdocs in recently granted programs focusing on developing and testing dearly needed joint on chip models for osteoarthritis.

CARCHIP will combine the expertise of the University of Twente (UTwente), chiron, Covaris, Stichting Proefdiervrij and the University of Maastricht (UM) to develop and implement a pioneering cartilage-on-chip model specifically designed for precision medicine in osteoarthritis (OA), the most common degenerative joint disease affecting more than 1.5 million Dutch citizens.  To study OA patient heterogeneity at the molecular level, primary cells and tissues obtained from osteoarthritic patients will be endotyped using advanced mass spectrometry-based proteomics. Endotype specific primary cell cultures will be then established using animal free culture media and will be genetically modified with bioluminescent reporters for OA endotype in vitro modelling.  These modified cells will be used to establish cartilage on chip cultures using a unique platform consisting of 24 cartilage on chip devices that can be simultaneously exposed to multidirectional loading mimicking cartilage forces in the moving human knee joint. We will validate this model by evaluating both established anti-inflammatory drugs and novel disease-modifying agents currently under development. Additionally, chiron will initiate essential steps toward the commercialization of this innovative platform, which has the potential to revolutionize the development of OA treatment strategies. By integrating advanced technologies such as MS and bioluminescent imaging with cutting-edge organ-on-chip models, the project aspires to enhance understanding of OA pathology and facilitate the development of targeted therapies. This approach not only aims to improve patient outcomes but also seeks to address the urgent need for more effective treatments for this prevalent condition which still cannot be treated effectively. Ultimately, the project will contribute significantly to the field of precision medicine, paving the way for personalized treatment plans that can better meet the needs of individuals suffering from OA, thereby reducing the overall healthcare burden associated with this chronic disease. Successful completion of the project will present the CARCHIP technology as a viable and more alternative for animal experimentation ultimately translating in a reduction of animal use..